VIVO Cannabis (VVCIF) Receives a New Rating from Clarus

By Ryan Adsit

VIVO Cannabis (VVCIFResearch Report) received a Buy rating and a $0.70 price target from Clarus analyst Noel Atkinson today. The company’s shares closed last Monday at $0.21, close to its 52-week low of $0.14.

According to TipRanks.com, Atkinson is ranked #282 out of 5855 analysts.

The the analyst consensus on VIVO Cannabis is currently a Hold rating.

See today’s analyst top recommended stocks >>

The company has a one-year high of $0.93 and a one-year low of $0.14. Currently, VIVO Cannabis has an average volume of 143.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VIVO Cannabis, Inc. engages in the cultivation and production of cannabis-based products. It operates through the following segments: Medical and Non-Medical Cannabis, Patient Clinic, and Corporate. The Medical and Non-Medical Cannabis segment produces and sells cannabis and cannabis-derived products for medical purposes and for the adult-use market.